Insider Buying: Profound Medical (TSE:PRN) Director Acquires 20,000 Shares of Stock

Key Points

• Director Dr. Arun Menawat purchased 20,000 shares on March 20 at C$6.96 each (C$139,200 total), increasing his stake to 658,660 shares — a 3.13% rise in ownership.
• The stock was last C$8.88 with a market cap of C$322.29M, a negative P/E of −6.30, a 12‑month range of C$5.23–C$12.40, and analysts forecast roughly −1.9 EPS for the current fiscal year.
• Profound Medical is a commercial‑stage medical device company known for its TULSA‑PRO MRI‑guided, incision‑free prostate ablation system marketed in Canada, the U.S., Germany and Finland.

Profound Medical Corp. (TSE:PRN - Get Free Report) Director Dr. Arun Menawat purchased 20,000 shares of the business's stock in a transaction dated Friday, March 20th. The stock was bought at an average cost of C$6.96 per share, for a total transaction of C$139,200.00. Following the purchase, the director owned 658,660 shares in the company, valued at C$4,584,273.60. This trade represents a 3.13% increase in their ownership of the stock.

Profound Medical Price Performance

Shares of Profound Medical stock remained flat at C$8.88 during trading on Friday. The company had a trading volume of 9,896 shares, compared to its average volume of 20,108. The company has a quick ratio of 14.98, a current ratio of 12.52 and a debt-to-equity ratio of 7.09. Profound Medical Corp. has a twelve month low of C$5.23 and a twelve month high of C$12.40. The business's fifty day simple moving average is C$8.89 and its 200-day simple moving average is C$8.98. The stock has a market cap of C$322.29 million, a price-to-earnings ratio of -6.30 and a beta of 1.10.

Profound Medical (TSE:PRN - Get Free Report) last released its quarterly earnings data on Thursday, March 5th. The company reported C$0.37 EPS for the quarter. Profound Medical had a negative return on equity of 85.73% and a negative net margin of 248.45%.The business had revenue of C$8.00 million during the quarter. On average, equities research analysts forecast that Profound Medical Corp. will post -1.9000001 EPS for the current fiscal year.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.